News stories about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.7813662313817 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of NASDAQ BCLI traded down $0.08 on Friday, reaching $3.92. 24,776 shares of the company’s stock traded hands, compared to its average volume of 41,603. Brainstorm Cell Therapeutics has a 12 month low of $2.88 and a 12 month high of $5.35. The company has a market capitalization of $82.68 million, a price-to-earnings ratio of -15.08 and a beta of 2.06.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its earnings results on Monday, July 23rd. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.02). research analysts forecast that Brainstorm Cell Therapeutics will post -0.49 earnings per share for the current year.

A number of brokerages have weighed in on BCLI. HC Wainwright set a $11.00 target price on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Friday, June 8th. Maxim Group set a $9.00 target price on shares of Brainstorm Cell Therapeutics and gave the company a “buy” rating in a research note on Friday, May 25th. Finally, ValuEngine raised shares of Brainstorm Cell Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, May 16th.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.

Featured Story: Book Value Per Share in Stock Trading

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with's FREE daily email newsletter.